Acceptability, feasibility and preliminary effectiveness of Picopulse for the treatment of melasma among Malaysian women: A pilot quasi‐experimental
Open Access
- 9 July 2023
- journal article
- research article
- Published by Wiley in JEADV Clinical Practice
- Vol. 3 (3) , 807-816
Abstract
Background: Women are greatly affected by melasma as compared to men and has a significant negative impact on their quality of life. Thus far, there are no well‐conducted trials for melasma in Malaysia.Objectives: This multicentre quasi‐experimental pilot study aims to determine the acceptability and feasibility of conducting a preliminary effectiveness trial for the Picopulse treatment effect on melasma severity and quality of life in Malaysian women.Methods: Outcome measures were collected from 32 participants aged 18–65 years old presenting dermal melasma with Fitzpatrick skin type III–V from OneDoc Skin Centres in Klang Valley, Malaysia at baseline, 2 weeks, and 4 weeks after intervention. All preliminary effectiveness analyses were performed under the terms of intention‐to‐treat.Results: Overall, the average score of Short Assessment of Patient Satisfaction (SAPS) was 22.2 (SD = 4.8), this demonstrated that the treatment was satisfied and well‐accepted by all patients. The recruitment and retention rates were 48.48% and 71.88%, respectively. Twenty‐five out of 32 patients completed all 10 treatments (78.13%). There were significant mean differences in Melasma severity index (MSI) score reported with partial eta square at 0.79 (p < 0.0001), physician global assessment (PGA) with partial eta square at 0.89 (p < 0.0001), and melasma quality of life scale (MELASQoL) with partial eta square at 0.32 (p < 0.05), from baseline measurement to 4 weeks postintervention. The three most common temporary side effects were pain (M = 0.2, SD = 0.46), redness (M = 0.12, SD = 0.24), and dryness (M = 0.11, SD = 0.17), however, all adverse effects were well‐tolerated and resolved without any treatments.Conclusions: These findings provide promising data that support the acceptability and feasibility for future full‐scale clinical studies. This study was registered with ClinicalTrials.gov (NCT04834167).Keywords
This publication has 27 references indexed in Scilit:
- A retrospective analysis on the management of pigmented lesions using a picosecond 755‐nm alexandrite laser in AsiansLasers in Surgery and Medicine, 2015
- Estimating the sample size for a pilot randomised trial to minimise the overall trial sample size for the external pilot and main trial for a continuous outcome variableStatistical Methods in Medical Research, 2015
- Melasma and assessment of the quality of life in Brazilian womenAnais Brasileiros de Dermatologia, 2015
- Measuring patient satisfaction with health care treatment using the Short Assessment of Patient Satisfaction measure delivered superior and robust satisfaction estimatesJournal of Clinical Epidemiology, 2014
- A Cross-Sectional, Multicentric Clinico-Epidemiological Study of Melasma in IndiaDermatology and Therapy, 2014
- Treatment of Tattoos With a Picosecond Alexandrite LaserArchives of Dermatology, 2012
- Measures of adult pain: Visual Analog Scale for Pain (VAS Pain), Numeric Rating Scale for Pain (NRS Pain), McGill Pain Questionnaire (MPQ), Short‐Form McGill Pain Questionnaire (SF‐MPQ), Chronic Pain Grade Scale (CPGS), Short Form‐36 Bodily Pain Scale (SF‐36 BPS), and Measure of Intermittent and Constant Osteoarthritis Pain (ICOAP)Arthritis Care & Research, 2011
- Melasma: A comprehensive updateJournal of the American Academy of Dermatology, 2011
- Guidelines for clinical trials in melasmaBritish Journal of Dermatology, 2006
- Development and validation of a health-related quality of life instrument for women with melasmaBritish Journal of Dermatology, 2003